Novartis committed to CAR-Ts – but doubts about commercial viability remain
cancer, Cancer Research Technology, CAR T, immunotherapy, Juno, Kite, Novartis, Oncology
0 Comment
Novartis may have concerns about commercial prospects, says expert.